Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results
SILVER SPRING, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2020. Financial Highlights Despite continuing impact from COVID-19, total net sales of $12.5 million for the fourth quarter of 2020, representing a 3% increase over the fourth quarter of 2019° Core Products net sales of $10.3 million in the fourth quarter of 2020, a 10% increase over the fourth quarter of 2019To
